期刊文献+

瑞替普酶与低相对分子质量肝素早期溶栓治疗急性心肌梗死的对比研究 被引量:6

Comparative the Effect of Thrombolytic Therapy using Rhteplase and Low Molecular Weight Heparin in Patients with Acute Myocardial Infarction
下载PDF
导出
摘要 目的 对比瑞替普酶联合低相对分子质量肝素(LMWH)治疗急性心肌梗死(AMI)患者的疗效和安全性.方法 选取2008年6月~2013年1月在本院治疗的AMI住院患者131例,随机分为A组(瑞替普酶组,67例)和B组(对照组,64例).两组在使用LMWH的基础上,A组使用瑞替普酶;B组使用生理盐水作为对照.观察对比两组的疗效和并发症发生率.结果 两组不良反应和并发症的发生率差异无统计学意义(P>0.05).A组的冠脉再通率59例(86.7%)与B组的47例(73.4%)比较明显增加,差异有统计学意义(χ2=4.532,P=0.033,P<0.05).结论 瑞替普酶联合LMWH治疗AMI是安全有效的,较单纯使用LMWH疗效明显. Objective To contrast the effect of thrombolytic therapy using rhteplase and low molecular weight heparin (LMWH)in patients with acute myocardial infarction (AMI). Methods 131 patients with AMI asmitted in our department from 2008. June ~ 2013. Jcnuory, randomly divided into group A (reteplase the gen- eral enzyme group,67 cases) ,and group B( control group,64 cases). Based on the LMWH in the two groups, reteplase was used in group A and saline was used in group B. Efficacy and complication rates of the two groups were compared. Results It is no significant difference between the two groups about the incidence of complications (P 〉 0.05 ). Compared with group B 47 cases (73.4%), group A 59 cases ( 86.7% ) coronary recanalization rate was increased,the difference was statistically significant difference( X2 =4. 532 ,P = 0. 033, P 〈 0.05 ). Conclusion Rhaetian the general enzyme combined with LMWH in the treatment of AMI event is safe and effective,than the simple use of LMWH is effective.
作者 杜相鹏 于云
出处 《血栓与止血学》 2013年第6期251-253,共3页 Chinese Journal of Thrombosis and Hemostasis
关键词 急性心肌梗死 瑞替普酶 低相对分子质量肝素 溶栓治疗 Acute myocardiak infarction Reteplas Low molecular weight heparin Thrombolytic therapy
  • 相关文献

参考文献9

二级参考文献76

共引文献107

同被引文献57

  • 1Ndrepepa G, Neumann FJ, Schulz S, et al. Incidence and prog- nostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age [ J ]. Catheter Cardiovasc In- terv, 2014, 83(2) : 182 -189.
  • 2Showkathali R, Davies JR, Parker M, et al. Comparison d bivaliru- din with heparin versus abciximab with heparin for primary pereu- taneous coronary intervention in " Real World" practice[ J ]. Card- iovasc Revasc Med, 2013, 14(5) : 289-293.
  • 3Rigattieri S, Cera M, Sciahbasi A, et ai. Primary percutaneous coronary intervention in nonagenarians : six - month outcomes from a single - center registry [ J ]. J Invasive Cardiol, 2013, 25 (5) : 242 - 245.
  • 4Mehilli J, Neumann FJ, Ndrepepa G, et al. Sex - related effec- tiveness of bivalirudin versus abciximab and heparin in non - ST - segment elevation myocardial infarction [ J ]. Am Heart J, 2013, 165(4) : 537 -543.
  • 5Shehon R, Efiyehiou C, Somers K, et al. Bivalirudin in patients undergoing primary peroutaneous coronary intervention for acute ST- elevation myocardial infarction: outcomes in a large real - world population[J]. EuroIntervention. 2013, 9( I ) : 118 - 124.
  • 6李翔.瑞替普酶静脉溶栓治疗急性心肌梗死80例分析[J].医学信息,2013,(26):134.
  • 7Tapanainen JM, Lindgren KS, Makikallio TH, et al. Natriuretic peptides as predictors of non-sudden cardiac death after acute myocardial infarc- tion in the beta-blocking eral [ J ]. J Am Coil Cardiol, 2014,43 ( 5 ) : 757 - 763.
  • 8Liu Y, Redetzke RA, Said S, et al. Serum thyroid hormone levels may not accurately reflect thyroid tissue levels and cardiac function in mild hypot- hyroidism [ J ]. Am J Physiol Heart Circ Physiol, 2008,294 ( 5 ) : 2137 - 2143.
  • 9Chamnarnphol N,Wisaratapong T,Cheevatanakornkul S.Cor- relation between percutaneous coronary intervention vol- ume,door-to-balloon time and mortality of patients with acute ST-segment elevation myocardial infarction[J].J Med Assoc Thai, 2012,95 (3) : 325-329.
  • 10李欢.阿替普酶与尿激酶溶栓治疗急性ST段抬高型心肌梗死临床疗效的对比研究[J].实用心脑肺血管病杂志,2015,23(3):147-148.

引证文献6

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部